Table 3 Correlation between GPX4 expression and clinical features
| Â | High-GPX4 | Low-GPX4 | P value |
|---|---|---|---|
No | 89 | 89 | Â |
Age (years) | 60.87 ± 10.53 | 58.65 ± 11.12 | 0.174 |
BMI (kg/m2) | 23.30 ± 2.88 | 23.78 ± 3.98 | 0.356 |
Sex | |||
 Males | 60 (67.4%) | 67 (71.3%) | 0.246 |
 Females | 29 (32.6%) | 22 (24.7%) | |
Tumor location | |||
 Fundus | 11 (12.4%) | 14 (15.7%) | 0.396 |
 Body | 23 (25.8%) | 29 (32.6%) | |
 Antrum | 55 (61.8%) | 46 (51.7%) | |
Differentiation | |||
 Well and Moderate | 28 (31.5%) | 27 (30.3%) | 0.871 |
 Poor | 61 (68.5%) | 62 (67.9%) | |
Lauren type | |||
 Intestinal-type | 35 (39.3%) | 32 (36.4%) | 0.463 |
 Diffuse | 33 (37.1%) | 28 (31.8%) | |
 Mixed-type | 21 (23.6%) | 28 (31.8%) | |
T stage | |||
 1 | 32 (36.0%) | 43 (48.3%) | 0.188 |
 2 | 20 (22.5%) | 11 (12.4%) | |
 3 | 20 (22.5%) | 16 (18.0%) | |
 4 | 17 (19.1%) | 19 (21.3%) | |
N stage | |||
0 | 48 (53.9%) | 45 (50.6%) | 0.836 |
 1 | 13 (14.6%) | 12 (13.5%) | |
 2 | 12 (13.5%) | 11 (12.4%) | |
 3 | 16 (18.0%) | 21 (23.6%) | |
M stage | |||
 0 | 88 (98.9%) | 89 (100%) | 0.316 |
 1 | 1 (1.1%) | 0 (0%) | |
TNM stage | |||
 I | 40 (44.9%) | 44 (49.4%) | 0.277 |
 II | 25 (28.1%) | 16 (18.0%) | |
 III | 23 (25.8%) | 29 (32.6%) | |
 IV | 1 (1.1%) | 0 (0%) | |
Adjuvant chemotherapy | |||
 Yes | 46 (51.7%) | 43 (48.3%) | 0.653 |
 No | 43 (48.3%) | 46 (51.7%) | |